The funding will boost the University of Nottingham spinout’s development of bone regeneration treatment
TherageniX, a company developing a dry powder gene therapy for bone graft augmentation, and the institution from which it emerged, the University of Nottingham, have been awarded a £995,000 grant from Innovate UK.
The funding will support the development of TherageniX’s powdered gene therapy, a non-viral gene delivery system to improve tissue regeneration after surgery. It will initially concentrate on orthopaedic applications, with the ultimate aim of improving outcomes for patients undergoing bone grafting procedures.
